Pharmaceutical group · Germany
BioNTech
A group of 4 companies with 74 medicines in 7 countries.
Group structure
4 companies in 2 countries
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine of every company in the group, current ones first.
1–25 of 74
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 22 | 17 | 5 | CompaniesAll medicines |
| Canada | 14 | 4 | 10 | CompaniesAll medicines |
| Netherlands | 12 | 12 | 0 | CompaniesAll medicines |
| Singapore | 11 | 11 | 0 | CompaniesAll medicines |
| Italy | 8 | 8 | 0 | CompaniesAll medicines |
| United States | 6 | 6 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, France, United Kingdom
Therapeutic areas
The ATC groups most of its medicines belong to, largest first.
- VaccinesAnti-infectives for systemic use · ATC J07B
Top substances
The active substances in most of its medicines.
- Tozinameran23 medicines
- Bretovameran11 medicines
- Famtozinameran11 medicines
- Covid-19 mrna vaccine7 medicines
- Cemivameran6 medicines
- Raxtozinameran6 medicines
- Mrna encoding lp.8.1.5 medicines
- *sarscov s-protein mrna,4 medicines
- Arnm con caperuza que codifica la proteina espiga del sars-cov-2, variante omicron xfg3 medicines
- Vacuna arnm que codifica la proteina la espicula viral del sars-cov-23 medicines
- Bnt162b2 omicron mrna3 medicines
- Riltozinameran3 medicines
- Mrna che codifica kp.21 medicine
- Mrna che codifica xfg1 medicine
- Mrna che codifica lp.8.11 medicine
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- biontech manufacturing
- biontech manufacturing marburg
- biontech pharmaceuticals asia pacific
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
All 16 sources
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Contains information from ACRA Information on Corporate Entities, accessed on 8 October 2026 through Data.gov.sg, under Singapore Open Data Licence version 1.0: https://data.gov.sg/open-data-licence. Structured selection and normalisation by Prognia; original UEN, field and retrieval date retained.
Licence: Singapore Open Data Licence
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.